Stroke prevention in the high-risk patient

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 12, 2007, Pages 1851-1859

  Spence, J David ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Anticoagulant; Antihypertensive; Antiplatelet; Bupropion; Endarterectomy; Nicotine patch; Vitamin

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; AMFEBUTAMONE; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; EPLERENONE; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; NICOTINE PATCH; OLIVE OIL; PIOGLITAZONE; RAPESEED OIL; RENIN; RIMONABANT; SPIRONOLACTONE; UNINDEXED DRUG; VARENICLINE; VITAMIN; WARFARIN;

AGING; ANGIOPLASTY; BLOOD PRESSURE REGULATION; CAROTID ARTERY DISEASE; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GYNECOMASTIA; HEALTH PROGRAM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; INCIDENCE; INTRACARDIAC THROMBOSIS; ISCHEMIC HEART DISEASE; LIDDLE SYNDROME; LIPOPROTEIN BLOOD LEVEL; LOW FAT DIET; MEDITERRANEAN DIET; POPULATION RESEARCH; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SECONDARY PREVENTION; SMOKING CESSATION; SODIUM RESTRICTION; STENT; TOBACCO DEPENDENCE;

AGING; ANTICOAGULANTS; ANTILIPEMIC AGENTS; CEREBROVASCULAR ACCIDENT; DIET; ENDARTERECTOMY, CAROTID; HUMANS; HYPERTENSION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SMOKING CESSATION;

EID: 34548225508     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.12.1851     Document Type: Review

References (81)

1. THOM T, HAASE N, ROSAMOND W et al.: Heart disease and stroke statistics - 2006 update a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 113(6):E85-E151.
2. ROTHWELL PM, COULL AJ, SILVER LE et al.: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial terriroties (Oxford Vascular Study). Lancet (2005) 366(9499): 1773-1783.
3. GORELICK PB: Stroke prevention. Arch. Neurol. (1995) 52(4):347-355.
4. HACKAM DG, SPENCE JD: Combining multiple approaches for the secondary prevention of vascular events after stroke. a quantitative modeling study. Stroke (2007) 38(6):1881-1885.
5. YUSUF S: Two decades of progress in preventing vascular disease. Lancet (2002) 360(9326):2-3.
6. ROTHWELL PM, WARLOW CP: Tuning of TIAs preceding stroke: time window for prevention is very short. Neurology (2005) 64(5):817-820.
7. WILLETT WC, STAMPFER MJ: Rebuilding the food pyramid. Sci. Am. (2003) 288(1):64-71.
8. LICHTENSTEIN AH, APPEL LJ, BRANDS M et al.: Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation (2006) 114(1):82-96.
9. GOLDSTEIN LB, ADAMS R, ALBERTS MJ et al.: Primary prevention of ischemic stroke: a guideline from the American Heart Association/ American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke (2006) (6):1583-1633.
10. SACKS FM, SVETKEY LP, VOLLMER WM et al.: Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med. (2001) 344(1):3-10.
11. DE LOEGERIL M, RENAUD S, MAMELLE N et al.: Mediterranean α-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet (1994) 343(8911):1454-1459.
12. SINGH RB, DUBNOV G, NIAZ MA et al.: Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high-risk patients (Indo-Mediterranean Diet Heart Study): a randomized single-blind trial. Lancet (2002) 360:1455-1461.
13. SPENCE JD: Nutrition and stroke prevention. Stroke (2006) 37(9):2430-2435.
14. CRITCHLEY JA, CAPEWELL S: Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA (2003) 290(1):86-97.
15. SACCO RL, ADAMS R, ALBERS G et al.: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke (2006) (2):577-617.
16. BURT A, THORNLEY P, ILLINGWORTH D, WHITE P, SHAW TR, TURNER R: Stopping smoking after myocardial infarction. Lancet (1974) 1(7852):304-306.
17. JORENBY DE, LEISCHOW SJ, NIDES MA et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation [See comments]. N. Engl. J. Med. (1999) 340(9):685-691.
18. TUCCI SA, HALFORD JC, HARROLD JA, KIRKHAM TC: Therapeutic potential of targeting the endocarmabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr. Med. Chem. (2006) 13(22):2669-2680.
19. CLELAND JG, GHOSH J, FREEMANTLE N et al.: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Fail. (2004) (4):501-508.
20. JORENBY DE, HAYS JT, RIGOTTI NA et al.: Efficacy of varenidine, an α4β2 nicotinic acetylcholine receptor panial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA (2006) 6(1):56-63.
21. COLLINS R, PETO R, MCMAHON S et al.: Blood pressure, stroke and coronary artery disease. Lancet (1990) 335:827-838 (abstract).
22. SPENCE JD: Antihypertensive drugs and prevention of atherosclerotic stroke. Stroke (1986) 17:808-810.
23. BASS MJ, MCWHINNEY IR, DONNER A: Do family physicians need medical assistants to detect and manage hypertension? CMAJ (1986) 134:1247-1255.
24. SPENCE JD: Physiologic tailoring of therapy for resistant hypertension: 20 year' experience with stimulated renin profiling. Am. J. Hypertens. (1999) 12:1077-1083.
25. BIRKETT NJ, DONNER AP, MAYNARD M: Prevalence and control of hypertension in an Ontario county. Can. Med. Assoc. J. (1985) 132(9):1019-1024.
26. SPENCE JD: Cerebral consequences of hypertension. In: Hypertension: Pathophysiology, Diagnosis, and Management. 2nd Edition. Laragh JH, Brenner B (Eds), Raven Press, New York (1995):741-753.
27. BARNETT HJ, TAYLOR DW, ELIASZIW M et al.: Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators [See comments]. N. Engl. J. Med. (1998) 339(20):1415-1425.
28. PROGRESS COLLABORATIVE GROUP: Randomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack Lancet (2001) 358:1033-1041.
29. DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and morality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359(9311):995-1003.
30. SCHRADER J, LUDERS S, KULSCHEWSKI A et al.: Morbidity and mortality after stroke, eprosatran compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke (2005) 36(6):1218-1226.
31. THE ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLCHAT). JAMA (2002) 288(23):2981-2997.
32. WING LM, REID CM, RYAN P et al.: Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Clin. Exp. Hypertens. (1997) 19(5-6):779-791.
33. DAHLOF B, SEVER PS, POULTER NR et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 366(9489):895-906.
34. SPENCE JD: Individualized therapy for hypertension. Hypertension (2006) 47(3):E11.
35. LARAGH JH: Modern system for treating high blood pressure based on renin profiling and vasoconstriction-volume analysis: a primary role for β-blocking drugs such as propranolol. Am. J. Med. (1976) 61:797-810.
36. WALLACH L, NYARAI I, DAWSON KG: Stimulated renin: a screening test for hypertension. Ann. Intern. Med. (1975) 82:27-34.
37. SPENCE JD: Management of resistant hypertension in patients with carotid stenosis: high prevalence of renovascular hypertension. Cerebrovasc. Dis. (2000) 10:249-254.
38. SPENCE JD: Treatment options for renovascular hypertensiom Expert Opin. Pharmacother. (2002) 3:411-416.
39. BIGLIERI EG, KATER CE, ARTEAGA EE: Primary aldosteronism is composed of primary adrenal hyperplasia and adenoma. J. Hypertens. (1984) 2(Suppl.):S259-S261.
40. BAKER EH, DUGGAL A, DONG Y et al.: Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension. Hypertension (2002) 40:13-17.
41. SWIFT PA, MACGREGOR GA: Genetic variation in the epithelial sodium channel: a risk factor for hypertension in people of African origin. Adv. Ren. Replace Ther. (2004) 11(1):76-86.
42. TAYLOR DW, BARNETT HJ, HAYNES RB et al.: Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet (1999) 353(9171):2179-2184.
43. HALKES PH, VAN GJ, KAPPELLE LJ, KOUDSTAAL PJ, ALGRA A: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet (2006) 367(9523):1665-1673.
44. ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (2002) 324(7329):71-86.
45. CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348(9038):1329-1339.
46. NORRIS JW, HACHINSKI VC, MYERS MG, CALLOW J, WONG T, MOORE RW: Serum cardiac enzymes in stroke. Stroke (1979) 10(5):548-553.
47. HUTCHINSON EC, ACHESON EJ: Strokes Natural History Pathology and Surgical Treatment. London, WB Saunders Co. Ltd. (1975).
48. SAXENA R, KOUDSTAAL PJ: Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst. Rev. (2004) (2):CD000185.
49. HUMPHRIES KH, JACKEVICIUS C, GONG Y et al.: Population rates of hospitalization for atrial fibrillation/flutter in Canada. Can. J. Cardiol. (2004) 20(9):869-876.
50. ELIASSON M, LINDAHL B, LUNDBERG V, STEGMAYR B: Diabetes and obesity in Northern Sweden: occurrence and risk factors for stroke and myocardial infarction. Scand. J. Public Health Suppl. (2003) 61:70-77.
51. SELVIN E, CORESH J, SHAHAR E, ZHANG L, STEFFES M, SHARRETT AR: Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Lancet Neurol. (2005) 4(12):821-826.
52. DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complicatiom trial. Diabetes (1995) 44(8):968-983.
53. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837-583.
54. THE DIABETES CONTROL AND COMPLICATIONS (DCCT) RESEARCH GROUP: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. (1995) 47(6):1703-1720.
55. THE DIABETES CONTROL AND COMPLICATIONS (DCCT) RESEARCH GROUP: Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am. J. Cardiol. (1995) 75(14):894-903.
56. STETTLER C, ALLEMANN S, JUNI P et al.: Glycemic control and macrovascular disease in Types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am. Heart J. (2006) 152(1):27-38.
57. WILCOX R, BOUSSER MG, BETTERIDGE DJ et al.: Effects of pioglitazone in patients with Type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke (2007) 38(3):865-873.
58. EUROPEAN CAROTID SURGERY TRIALISTS' COLLABORATIVE GROUP: Randomised trial of endarterectomy for recendy symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet (1998) 351:1379-1387.
59. EXECUTIVE COMMITTEE FOR THE ASYMPTOMATIC CAROTID ATHEROSCLEROSIS STUDY: Endarterectomy for asymptomatic carotid artery stenosis. J. Am. Med. Assoc. (1995) 272:1421-1428.
60. ROTHWELL PM: ACST: which subgroups will benefit most from carotid endarterectomy? Lancet (2004) 364(9440): 1122-1123.
61. KRESOWIK TF, BRATZLER D, KARP HR et al.: Multistate utilization, processes, and outcomes of carotid endarterectomy. J. Vasc. Surg. (2001) 33(2):227-234.
62. PERRY JR, SZALAI JP, NORRIS JW; FOR THE CANADIAN STROKE CONSORTIUM: Consensus against carotid surgery and screening for asymptomatic stenosis. Arch. Neurol. (1997) 54:25-28.
63. SPENCE JD, TAMAYO A, LOWNIE SP, NG WP, FERGUSON GG: Absence of microemboli on transcranial Doppler identifies low-risk patients with asymptomatic carotid stenosis. Stroke (2005) 36(11):2373-2378.
64. MARKUS HS, MACKINNON A: Asymptomatic embolization detected by doppler ultrasound predicts stroke risk in symptomatic carotid artery stenosis. Stroke (2005) 36:971-975.
65. HACHINSKI V, GRAFFAGNINO C, BEAUDRY M et al.: Lipids and stroke: a paradox resolved. Arch. Neurol. (1996) 53(4):303-308.
66. AMARENCO P, LAVALLEE P, TOUBOUL PJ: Stroke prevention, blood cholesterol, and statins. Lancet Neurol. (2004) 3(5):271-278.
67. AMARENCO P, BOGOUSSLAVSKY J, CALLAHAN A III et al.: High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. (2006) 355(6):549-559.
68. BONAA KH, NJØLSTAD I, UELAND PM et al.: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. (2006) 354(15):1578-1588.
69. GRAHAM IM, DALY L, REFSUM H, ROBINSON K et al.: Plasma homocysteine as a risk factor for vascular disease. JAMA (1997) 277:1775-1781.
70. NYGÅRD O, NORDREHAUG JE, REFSUM H, UELAND PM, FARSTAD M, VOLLSET SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. (1997) 337:230-236.
71. LOFFREDO L, VIOLI F, FIMOGNARI FL et al.: The association between hyperhomocysteinemia and ischemic stroke in patients with non-valvular atrial fibrillation. Haematologica (2005) 90(9):1205-1211.
72. POLI D, ANTONUCCI E, CECCHI E et al.: Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke (2005) 36(10):2159-2163.
73. LONN E, YUSUF S, ARNOLD MJ et al.: Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. (2006) 354(15):1567-1577.
74. REFSUM H, SMITH AD: Homocysteine, B vitamins, and cardiovascular disease. N. Engl. J. Med. (2006) 355(2):207-211.
75. NAYLOR AR, BOLIA A, ABBOTT RJ et al.: Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: a stopped trial. J. Vasc. Surg. (1998) 28(2):326-334.
76. MAS JL, CHATELLIER G, BEYSSEN B: Carotid angioplasty and stenting with and without cerebral protection: clinical alert from the endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis (EVA-3S) trial. Stroke (2004) 35(1):E18-E20.
77. ALBERTS MJ; FOR THE PUBLICATIONS COMMITTEE OF THE WALLSTENT: Results of a multicenter prospective randomized trial of carotid artery stenting vs carotid endarterectomy. Stroke (2001) 32:325 (Abstract).
78. HALLIDAY A, MANSFIELD A, MARRO J et al.: Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet (2004) 363(9420):1491-1502.
79. CAVATAS INVSTIGATORS: Endovascular versus surgical treatment in patients with carotid stenosis in the carotid and vertebral artery transluminal angioplasty study (CAVATAS): a randomised trial. Lancet (2001) 357(9270):1729-1737.
80. YADAV JS, WHOLEY MH, KUNTZ RE et al.: Protected carotid-artery stenting versus endarterectomy in high-risk patients. N. Engl. J. Med. (2004) 351(15):1493-1501.
81. HOBSON RW: CREST (Carotid Revascularization Endarterectomy versus Stent Trial): background, design, and current status. Semin. Vasc. Surg. (2000) 13(2):139-143.